Baird Capital Invests in Virtual Incision

The pioneering medical device company raised $46 million in a Series C funding round led by Baird Capital and Endeavour Vision with participation from returning investor Bluestem Capital and others. The funds will be used to support regulatory and clinical programs leading to the commercialization of the company’s MIRA^® (“miniaturized in vivo robotic assistant”) Surgical Platform.

Headquartered in Lincoln, Neb., Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. The MIRA^® Platform is a first-of-its-kind miniaturized surgical robotic support device, focusing first on colon resection, with follow-on specialty robots for additional potential applications.

“MIRA is a space-saving solution designed to help hospitals and ambulatory surgery centers leverage their existing infrastructure to perform surgery efficiently while offering a low total cost of ownership,” said Amy Len Kobe, Principal with Baird Capital. “Consistent with our venture team’s investment goals, the MIRA platform has the ability to improve care for patients, physicians, providers, and payors. And, best of all, it’s unlike any other surgical robotic platform available today.”